Patents Assigned to Array Biopharma Inc.
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
    Publication number: 20090215834
    Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 5, 2008
    Publication date: August 27, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
    Publication number: 20090209542
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 5, 2008
    Publication date: August 20, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallance, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 7576114
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: August 18, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7576072
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 18, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, T. Brian Hurley, Allison L. Marlow, James Blake
  • Imidazopyrazines as Raf inhibitor compounds
    Patent number: 7566716
    Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: July 28, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Ellen Laird, George Topalov, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse
  • NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20090169510
    Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: April 18, 2008
    Publication date: July 2, 2009
    Applicants: InterMune, Inc., Array BioPharma, Inc.
    Inventors: Lawrence M Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
  • Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
    Patent number: 7553842
    Abstract: Disclosed are compounds of the Formula I and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: June 30, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Stephen T. Schlacter, John J. Gaudino, Laurence E. Burgess, Kevin W. Hunt
  • 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
    Publication number: 20090156603
    Abstract: Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Application
    Filed: March 23, 2007
    Publication date: June 18, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
  • Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
    Publication number: 20090148407
    Abstract: The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: July 17, 2006
    Publication date: June 11, 2009
    Applicants: Intermune, Inc., Array Biopharma Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
  • P38 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20090136596
    Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
    Type: Application
    Filed: February 2, 2009
    Publication date: May 28, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Method of treating inflammatory diseases
    Patent number: 7538120
    Abstract: Disclosed are methods of treating inflammatory diseases and disorders, such as arthritis and inflammatory bowel disease, in mammals.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: May 26, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Kevin Koch, T. Brian Hurley, Hong Woon Yang, Joseph Lyssikatos, James F. Blake, Allison L. Marlow, Eli M. Wallace
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE
    Publication number: 20090131435
    Abstract: Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, and X are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 20, 2009
    Publication date: May 21, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • P38 inhibitors and methods of use thereof
    Patent number: 7521447
    Abstract: This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: April 21, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7517994
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: April 14, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7511058
    Abstract: Disclosed are compounds of the Formula III and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 R10, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: March 31, 2009
    Assignee: Array BioPharma Inc.
    Inventors: T. Brian Hurley, Eli M. Wallace, Joseph P. Lyssikatos, James Blake
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 7501427
    Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: March 10, 2009
    Assignee: Array BioPharma, Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20090048224
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 19, 2009
    Applicants: Amgen, Inc., Array BioPharma, Inc.
    Inventors: Robert D. Groneberg, Benny C. Askew, JR., Derin C. D'Amico, James Zhan, Andras Toro, Youngboo Kim, David A. Mareska, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Chenguang Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Jeffrey Chen, Rana Nomak
  • RAF inhibitor compounds and methods
    Patent number: 7491829
    Abstract: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 17, 2009
    Assignees: Array Biopharma Inc., Genentech, Inc.
    Inventors: Ellen Laird, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse, Alan Olivero, George Topalov
  • Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
    Patent number: 7488823
    Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: February 10, 2009
    Assignee: Array Biopharma, Inc.
    Inventors: Eli Wallace, George Topolov, Qian Zhao, Joseph P. Lyssikatos
  • Bicyclic inhibitors of MEK and methods of use thereof
    Patent number: 7485643
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R20, R21, and R22 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: February 3, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, Joseph P. Lyssikatos, Hong Woon Yang